Le Lézard
Classified in: Health
Subjects: PDT, SCZ

BioPhotas, Inc. Launches the Newest Model of the Celluma Series


ANAHEIM, Calif., Jan. 3, 2018 /PRNewswire/ -- BioPhotas, Inc. announces the commercial introduction of the Celluma HOME, a fourth model in the Celluma Series of light therapy devices. Offered at an introductory price of $599.00, the Celluma HOME specifically addresses the challenges of Baby Boomers who struggle with wrinkles, aches and pain. FDA-cleared for over-the-counter purchase, the Celluma HOME treats eight separate aging challenges faced by the Baby Boomer, including full face wrinkles, arthritis, muscle and joint pain, muscle spasms and poor blood circulation.

Commenting on the launch of the Celluma HOME, Patrick Johnson, President & Chief Executive Officer for BioPhotas said, "From the very start, our goal at BioPhotas was to bring an FDA-cleared medical device directly to the consumer at home with the efficacy of large professional panels, but with the affordability of small hand-held devices. We believe we have achieved this with the Celluma HOME. Designed to treat a wide range of skin, muscle and joint conditions, anywhere on the body, the Celluma HOME gives the consumer the benefit of multiple hand-held devices in a single light panel with a significantly larger in treatment area."  

The Celluma HOME delivers blue, red and near-infrared light energy to safely address a wide variety of musculoskeletal and dermatological conditions. Each wavelength is absorbed by different molecules which act as a signaling mechanism for different cellular processes. With a treatment area that measures 14" by 6", the Celluma HOME is several times larger than typical hand-held light therapy devices. The Celluma's patented shape-taking light panel facilitates effective energy absorption by tissue by molding closely to any apart of the body, producing more efficient outcomes. 

The Celluma Series of light therapy devices is protected by both United States and Foreign utility patents and is CE-marked as a Dermal Wound Healing device. Further commenting on the launch of the Celluma HOME, Mr. Johnson noted, "[T]he Celluma HOME is a two-mode device designed specifically for the Baby Boomer who is interested in looking better and feeling better, and who wants to address those desires in the convenience of their own home." 

About BioPhotas, Inc.
In providing unique devices founded on NASA-developed technology and backed by clinical studies, BioPhotas is bringing to market safe, effective and affordable devices that unlock the clinical power of biophotonics. BioPhotas develops and markets devices for healthcare providers and consumers that conveniently treat a variety of skin, muscle and joint conditions. For more information about the Celluma please visit www.biophotas.com.

CONTACT:                                                                  
Patrick Johnson ? CEO
BioPhotas, Inc.
[email protected] 
7149780080

SOURCE BioPhotas, Inc.


These press releases may also interest you

19 avr 2024
Remedium Healthcare Products is proud to announce the launch of NuVeria Labs' revolutionary Sacral Silicone Dressing, now available for purchase on Amazon, bringing advanced wound care solutions directly to consumers' doorsteps. Designed to address...

19 avr 2024
Getting specialty medications into...

19 avr 2024
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. "This product, along with our other innovations,...

19 avr 2024
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...

19 avr 2024
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

19 avr 2024
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...



News published on and distributed by: